Chemomab Therapeutics (NASDAQ:CMMB) Stock Rating Upgraded by Oppenheimer

Chemomab Therapeutics (NASDAQ:CMMB) was upgraded by analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a note issued to investors on Monday, Marketbeat.com reports. The firm presently has a $6.00 price objective on the stock.

Chemomab Therapeutics Trading Up 4.2 %

Shares of CMMB opened at $0.89 on Monday. The company’s fifty day simple moving average is $0.74 and its 200 day simple moving average is $0.64. Chemomab Therapeutics has a 1-year low of $0.42 and a 1-year high of $1.89. The company has a market cap of $9.82 million, a price-to-earnings ratio of -0.42 and a beta of 0.39.

Chemomab Therapeutics (NASDAQ:CMMB) last announced its earnings results on Thursday, March 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.14. During the same quarter in the prior year, the firm posted ($0.72) earnings per share. As a group, research analysts forecast that Chemomab Therapeutics will post -1.2 earnings per share for the current year.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).